Using Proteomic Mass Spectrometry Imaging to Detect Malignant Melanoma

“Stephen Turner is Chief Executive Officer and Chairman of the Board Protea, positions he has held since founding the company in July, 2001. From 1999 to 2001 he served as President and CEO of Quorum Sciences, Inc. From 1984 to 1997 he was President and CEO of Oncor, Inc.He founded Bethesda Research Laboratories, Inc. in 1975 and served as its Chairman and CEO from 1975 to 1983, at which time BRL became the molecular biology division of Life Technologies, Inc.”

“Today, using anatomic pathology, the differences in appearance of a normal or a malignant lesion can be difficult to tell when just using light microscopy. About 25% of the biopsies that are taken, which is approximately two million per year in the United States, come back as indeterminable and need to be sent out to experts for further study.  These biopsies may display characteristics of both benign and malignant lesions.  It’s for those indeterminates that we are seeing our testing being of particular use.”

Read full article: Using proteomic mass spectrometry imaging to detect malignant melanoma: an interview with Stephen Turner